Canon Medical Systems receives 510(k) clearance for its Advanced intelligent Clear-IQ Engine.
MR image reconstruction could see a step forward.
Canon Medical Systems announced Wednesday it has received 510(k) clearance from the U.S. Food & Drug Administration for its Advanced intelligent Clear-IQ Engine (AiCE). This tool is designed for the Vantage Galan 3T MR system and expands access to the company’s Deep Learning Reconstruction (DLR) technology.
According to a company statement, the technology, which is also available across Canon Medical’s CT product portfolio, employs a deep learning algorithm to distinguish true MR signal from noise, suppressing the noise while simultaneously enhancing the signal.
“With the expansion of this unique DLR method across modalities and into MR, we’re elevating diagnostic imaging capabilities for our customers by bringing the power of AI to routine imaging to provide more possibilities in improving patient care than ever before,” said Jonathan Furuyama, managing director of Canon Medical Systems USA, Inc.’s MR business unit.
Trained on a significant amount of high-quality image data, AiCE has a deep learning neural network that can, potentially, reduce noise and boost the MR signal for quicker delivery of clear, distinct images. Based on the company statement, the technology offers these capabilities:
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Systematic Review: PET/MRI May be More Advantageous than PET/CT in Cancer Imaging
July 18th 2024While PET/MRI and PET/CT had comparable sensitivity for patient-level regional nodal metastases and lesion-level recurrence, the authors of a systematic review noted that PET/MRI had significantly higher accuracy in breast cancer and colorectal cancer staging.